GlassScriptPhysician profile
Ravinder K Arora
NPI 1952307720
$1,110.80
in general payments reported to CMS, 2019-2025
23 companies · $94.89 in 2025
The $94.89 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $29.27 · 2021: $39.08 · 2022: $16.57 · 2024: $24.30 · 2025: $94.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $119.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $183.70 | 2019-2021 | |
| Lilly USA, LLC | $139.50 | 2019 | |
| Amgen INC. | $99.95 | 2019 | |
| Medtronic, INC. | $94.89 | 2025 | Signia |
| Pharmacyclics LLC, An Abbvie Company | $69.30 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $68.97 | 2019 | |
| Genentech USA, INC. | $65.46 | 2019 | |
| Tesaro, INC. | $56.40 | 2019 | |
| Janssen Biotech, INC. | $46.08 | 2019 | |
| Merck Sharp & Dohme LLC | $34.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.87 | 2019 | |
| Daiichi Sankyo INC. | $24.30 | 2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $24.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.68 | 2019 | |
| Pfizer INC. | $20.33 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.56 | 2019 | |
| Eisai INC. | $19.41 | 2019 | |
| Apo-Pharma USA, INC. | $18.70 | 2019 | |
| Astellas Pharma US INC | $18.46 | 2019 | |
| Acrotech Biopharma INC. | $16.57 | 2022 | |
| Array Biopharma INC | $13.00 | 2019 | |
| Gilead Sciences, INC. | $12.97 | 2019 | |
| Seagen INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravinder Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.